ContraVir Pharmaceuticals’ (CTRV) “Buy” Rating Reiterated at Maxim Group
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a research report issued on Thursday. They presently have a $4.00 target price on the biopharmaceutical company’s stock. Maxim Group’s price objective would suggest a potential upside of 75.82% from the company’s current price.
ContraVir Pharmaceuticals (NASDAQ:CTRV) traded up 17.9133% during mid-day trading on Thursday, hitting $2.3111. 25,774,272 shares of the stock traded hands. ContraVir Pharmaceuticals has a 52 week low of $0.76 and a 52 week high of $2.65. The firm’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.06. The firm’s market cap is $124.00 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Prospera Financial Services Inc raised its position in ContraVir Pharmaceuticals by 0.6% in the second quarter. Prospera Financial Services Inc now owns 178,550 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 1,000 shares in the last quarter. Vanguard Group Inc. raised its position in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock valued at $952,000 after buying an additional 73,135 shares in the last quarter. Finally, Teachers Advisors Inc. raised its position in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock valued at $1,102,000 after buying an additional 141,368 shares in the last quarter.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of virology drugs to treat diseases of unmet needs, such as herpes zoster and hepatitis B (HBV). It is developing targeted antiviral therapies with over two drug candidates in clinical studies. Its FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or VZV.
Receive News & Stock Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.